Clinical trial Recruiting at 1 site Interventional Ages 20 to 65 Women only

Pectoral nerve block versus thoracic paravertebral block to prevent chronic pain after mastectomy

Official title: Pectoral Nerve Block Versus Paravertebral Block In The Incidence of Chronic Pain After Breast Cancer Surgery: A Randomized Clinical Trial

Run by Assiut University · NCT06082206 · Data updated 2026-11-12

This trial will test whether a pectoral (PECS) block or a thoracic paravertebral (TPVB) block given during mastectomy better prevents long-term chest, axillary, or arm pain in adult women.

More Chronic Pain trials

Quick facts

Study typeInterventional
Ages20 Years to 65 Years
SexWomen only
Enrollment90 (estimated)
SponsorAssiut University
Academic / other
Locations1 site (Asyut)
StatusRecruiting
StartedNovember 15, 2023
Main results expectedAugust 2026
Study endsAugust 2026
Registry record updatedJuly 6, 2026
Trial IDNCT06082206 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Women aged 20–65 years with BMI 25–35 and ASA I–III who are scheduled for unilateral mastectomy (with or without axillary node dissection) are ideal candidates.

Probably not a fit

Men, pregnant or breastfeeding women, patients with active malignant disease, bilateral or recent ipsilateral breast surgery, life expectancy under two years, or those outside the stated age/BMI/health criteria would not be eligible and are unlikely to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adult women undergoing mastectomy under general anesthesia receive either an ultrasound-guided thoracic paravertebral block (TPVB) or pectoral nerve blocks (PEC I/II) in addition to standard postoperative analgesia, and their pain, shoulder function, and complications are followed after surgery. The trial enrolls patients aged 20–65 with BMI 25–35 and ASA I–III who are having unilateral mastectomy with or without axillary lymph node or sentinel node dissection. Ultrasound guidance is used to increase block accuracy and reduce complications, and outcomes include incidence of chronic post-mastectomy pain as well as acute analgesic effectiveness and adverse events. Follow-up includes postoperative pain assessments and longer-term evaluation for development of chronic pain.

Why it matters

Potential benefit: If one block proves superior, patients could have lower rates of chronic post-mastectomy pain, faster recovery, and reduced opioid use.

How similar studies have gone: Previous trials show both TPVB and PECS blocks reduce acute postoperative pain after breast surgery, but evidence is mixed about which approach better prevents chronic post-mastectomy pain.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* ASA grade I, II, or III female patients in the age group of 20-65 years
* with body mass index (BMI) of 25-35 who were undergoing mastectomy with or without axillary lymph node or sentinel lymph node dissection or partial mastectomy (sparing the skin, areola, and nipple) with axillary lymph node dissection

Exclusion Criteria:

* male sex; patient refusal,
* a life expectancy less than 2 yr;
* active malignant disease; pregnant or breastfeeding women;
* bilateral surgery; ipsilateral breast surgery in the past 3 yr;

Where it's running

  • Assiut governorate
    Asyut, Egypt
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.